Compare Charles River Laboratories Intl. Inc (CRL) vs Dolby Laboratories, Inc. (DLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Dolby Laboratories, Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $284.47 (market cap $13.46B), while Dolby Laboratories, Inc. trades at $60.3 (market cap $5.75B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 2.3× Dolby Laboratories, Inc.'s market cap, and Dolby Laboratories, Inc. pays a 2.35% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | DLB | |
|---|---|---|
Market Cap | $13.46B | $5.75B |
Sector | Health | Industrials |
52-Week High | $282.00 | $75.62 |
52-Week Low | $145.57 | $48.51 |
Enterprise Value | $16.30B | $5.12B |
Dividend Yield | — | 2.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
DLB trades at $60.90, down 1.93% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company has consistently beaten EPS estimates in recent quarters, including Q2 2026 with $0.69 actual versus $0.67 expected. Revenue has been stable around $1.3B annually, with a strong gross profit margin of 87.61% in 2025. Analyst consensus is a Buy with a price target of $87.50, suggesting significant upside. Recent news highlights growth in Dolby Atmos and automotive licensing.
The outlook for DLB is positive, supported by strong fundamentals and analyst optimism, but near-term execution risks and licensing volatility pose challenges. The stock's current valuation metrics, including a P/E of 26.11, appear reasonable given growth prospects. Key risks include revenue fluctuations and competitive pressures in the audio-video sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →
